ZyVersa Therapeutics Faces Delisting Notice

Ticker: ZVSA · Form: 8-K · Filed: Jul 16, 2025 · CIK: 1859007

Zyversa Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyZyversa Therapeutics, Inc. (ZVSA)
Form Type8-K
Filed DateJul 16, 2025
Risk Levelhigh
Sentimentbearish

Sentiment: bearish

Topics: delisting, listing-standards, regulatory-filing

TL;DR

ZyVersa Therapeutics got a delisting warning from the SEC.

AI Summary

ZyVersa Therapeutics, Inc. filed an 8-K on July 15, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, formerly Larkspur Health Acquisition Corp., is incorporated in Delaware and has its principal executive offices in Weston, Florida.

Why It Matters

This filing indicates potential issues with ZyVersa Therapeutics' continued listing on an exchange, which could impact its stock trading and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's ability to remain publicly traded.

Key Numbers

  • 001-41184 — SEC File Number (Identifies the company's filing history with the SEC.)
  • 86-2685744 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

  • ZyVersa Therapeutics, Inc. (company) — Registrant
  • Larkspur Health Acquisition Corp. (company) — Former Company Name
  • July 15, 2025 (date) — Date of Report
  • Delaware (jurisdiction) — State of Incorporation
  • Weston, Florida (location) — Principal Executive Offices

FAQ

What specific listing rule or standard did ZyVersa Therapeutics fail to satisfy?

The filing does not specify the exact rule or standard that was not met, only that a notice of delisting or failure to satisfy a continued listing rule or standard was issued.

When was ZyVersa Therapeutics previously known as Larkspur Health Acquisition Corp.?

The date of the name change from Larkspur Health Acquisition Corp. to ZyVersa Therapeutics, Inc. was April 26, 2021.

What is the primary business of ZyVersa Therapeutics, Inc.?

ZyVersa Therapeutics, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.

Where are ZyVersa Therapeutics' principal executive offices located?

The principal executive offices are located at 2200 N. Commerce Parkway, Suite 208, Weston, Florida 33326.

What is the filing date of this Current Report on Form 8-K?

The date of the report, and the earliest event reported, is July 15, 2025.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on July 16, 2025 regarding ZyVersa Therapeutics, Inc. (ZVSA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.